Recent Advances in Oral Prodrug Discovery

作者: Aesop Cho

DOI: 10.1016/S0065-7743(06)41027-7

关键词: BiochemistryTranscellularSolubilityTransporterChemistryLipophilicityProdrugIntestinal mucosaMonocarboxylic Acid TransportersAmino acid

摘要: Publisher Summary A number of new prodrug tactics have been devised to address issues associated with parent drugs or lead compounds, such as solubility, permeability, and tissue distribution. This chapter discusses prodrugs poorly soluble polar targeting active transporters, for targeted delivery. Compounds are considered be when their oral bioavailability is limited by the rate extent dissolution in gastrointestinal (GI) tract. typical strategy cases focuses on chemical derivatization improve water solubility. Highly polar, ionizable promoieties often required obtain an adequate level Prodrug compounds primarily directed toward increasing lipophilicity enhance passive transcellular absorption, while retaining acceptable Accordingly, design involves masking hydrogen-bonding groups appropriate promoieties. Mechanistic studies intestinal transepithelial transport revealed that absorption certain structural classes enhanced membrane-bound transporters. Such proteins include peptide amino acid nucleoside bile monocarboxylic One more recent endeavors field has selectively deliver principles target tissues. For this approach effective, must absorbed intact through mucosa, resistant metabolism enterocytes plasma, taken up reconverted parents

参考文章(33)
O. Helen Chan, Heidi L. Schmid, Linda A. Stilgenbauer, William Howson, David C. Horwell, Barbra H. Stewart, Evaluation of a targeted prodrug strategy of enhance oral absorption of poorly water-soluble compounds. Pharmaceutical Research. ,vol. 15, pp. 1012- 1018 ,(1998) , 10.1023/A:1011969808907
Michael D. Taylor, Improved passive oral drug delivery via prodrugs Advanced Drug Delivery Reviews. ,vol. 19, pp. 131- 148 ,(1996) , 10.1016/0169-409X(95)00104-F
William A. Lee, Gong-Xin He, Eugene Eisenberg, Tomas Cihlar, Swami Swaminathan, Andrew Mulato, Kenneth C. Cundy, Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue Antimicrobial Agents and Chemotherapy. ,vol. 49, pp. 1898- 1906 ,(2005) , 10.1128/AAC.49.5.1898-1906.2005
Stephanie L Ciesla, Julissa Trahan, W.Brad Wan, James R Beadle, Kathy A Aldern, George R Painter, Karl Y Hostetler, Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney Antiviral Research. ,vol. 59, pp. 163- 171 ,(2003) , 10.1016/S0166-3542(03)00110-4
Franck Desmoulin, Véronique Gilard, Myriam Malet-Martino, Robert Martino, Metabolism of Capecitabine, an Oral Fluorouracil Prodrug:19F NMR Studies in Animal Models and Human Urine Drug Metabolism and Disposition. ,vol. 30, pp. 1221- 1229 ,(2002) , 10.1124/DMD.30.11.1221
Anne Engelbrecht Thomsen, Michael Søberg Christensen, Morten Aavad Bagger, Bente Steffansen, Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells European Journal of Pharmaceutical Sciences. ,vol. 23, pp. 319- 325 ,(2004) , 10.1016/J.EJPS.2004.08.005
Soumyajit Majumdar, Sridhar Duvvuri, Ashim K Mitra, Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development Advanced Drug Delivery Reviews. ,vol. 56, pp. 1437- 1452 ,(2004) , 10.1016/J.ADDR.2004.02.006
Laëtitia Bouérat, Jef Fensholdt, Xifu Liang, Sophie Havez, Simon F. Nielsen, Jens R. Hansen, Simon Bolvig, Christina Andersson, Indolin-2-ones with High in Vivo Efficacy in a Model for Multiple Sclerosis§ Journal of Medicinal Chemistry. ,vol. 48, pp. 5412- 5414 ,(2005) , 10.1021/JM0504151
Diane E. Gingrich, Dandu R. Reddy, Mohamed A. Iqbal, Jasbir Singh, Lisa D. Aimone, Thelma S. Angeles, Mark Albom, Shi Yang, Mark A. Ator, Sheryl L. Meyer, Candy Robinson, Bruce A. Ruggeri, Craig A. Dionne, Jeffry L. Vaught, John P. Mallamo, Robert L. Hudkins, A New Class of Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Structure−Activity Relationships for a Series of 9-Alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the Identification of CEP-5214 and Its Dimethylglycine Ester Prodrug Clinical Candidate CEP-7055 Journal of Medicinal Chemistry. ,vol. 46, pp. 5375- 5388 ,(2003) , 10.1021/JM0301641